Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.
Kura Oncology stock rises 6% in premarket trading after receiving $30 million milestone payment from Kyowa Kirin for Phase 3 cancer drug trial advancement.